Ranjbar 2007.

Methods	Randomized controlled trial Duration: 1999‐2001
Participants	Number: 228 patients enrolled Inclusion criteria: (1) brucellosis clinical features including fever, sweats, arthralgia, hepatomegaly, splenomegaly, and/or signs of focal disease with a ≥1/160 standard tube agglutination titer of antibodies to Brucella; or (2) a tissue sample or blood culture positive for Brucella bacteria; or (3) a four‐fold increase in Wright titer in a two‐week interval with compatible clinical findings Exclusion criteria: Pregnant women, children under eight years of age, and patients with endocarditis and neurobrucellosis
Interventions	1‐ doxycycline 100 mg twice a day plus rifampicin 10 mg/kg body weight/day every morning, both taken orally for eight weeks 2‐doxycycline 100 mg twice a day and rifampicin 10 mg/kg body weight/day every morning, both taken orally for eight weeks, plus 7.5 mg/kg amikacin intramuscularly twice a day for seven days.
Outcomes	1‐relapse 2‐therapeutic failure 3‐symptom relief 4‐negative 2ME titer 5‐adverse drug reactions
Notes	Location: Sina Hospital, Hamedan, Iran Setting: hospitalised and ambulatory patients Source of funding: not mentioned
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Using a table of random numbers
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	High risk	Open study
Incomplete outcome data (attrition bias) All outcomes	High risk	114 patients were randomized to each group. In DR group, 3 did not take the drugs correctly, and 1 lost to follow up. In DRA group, 2 did not complete the treatment, and 2 lost to follow up. The proportion of missing outcomes compared with observed event was considerable.
Selective reporting (reporting bias)	Low risk	Important outcomes were reported
Other bias	Low risk